Skip to main content
Premium Trial:

Request an Annual Quote

SQI to Raise Up to $4.9M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced it plans to raise up to C$5 million ($4.9 million) through a non-brokered private placement.

The company plans to use net proceeds to fund its development and commercialization programs and for general working capital, it said in a statement. Among SQI's technologies is its SQiDworks Diagnostics fully automated fluidics workstation for use with its proprietary QuantiSpot microarray test. It also has a number of diagnostic panels for autoimmune diseases either available or under development.

Toronto-based SQI plans to offer up to 2 million units. Each unit, which is being priced at C$2.50, includes one share of the company's stock and a purchase warrant for half a share of common stock.

Each whole common share purchase warrant allows the holder to acquire one common share for C$5 for a two-year period starting from the date of issuance.

Closing of the placement will be on or about Aug. 12.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.